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MANY studies in animals have examined biochemical,
immune and histological changes during arthritis; how-
ever, the study of the effects of arthritis on mobility has
been largely neglected. Interleukin-1, administered by
the intraarticular route into hamster knee joints, resulted
in inhibition of spontaneous wheel running activity;
however, the effect was transient, lasting only through
the evening following IL-1 administration. A further in-
jection of IL-1 2 days later showed still greater inhibition
of running. The effect again did not extend beyond the
first evening after injection. IL-Ix and IL-I showed
equivalent effects on mobility, and no evidence was seen
for cooperative interaction between them. A 50% inhibi-
tion of running occurred at a dose of approximately
10 ng/knee of IL-10t. The effect appeared not to be sys-
temic since intraperitoneal injection required microgram
amounts of IL-1 for an equivalent inhibition. At the time
mobility hadbeen restored to normal, histological exami-
nation showed the continued presence of inflammatory
cells, soft tissue swelling and cartilage proteoglycan loss.
These results suggest a lack of correlation between inhi-
bition of mobility and histopathological changes in carti-
lage and soft tissue.
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Introduction
Interleukin-1 (IL-1) has been suggested as an im-
portant mediator of arthritic disease. It has been
shown in vitro to accelerate cartilage proteoglycan
lOSS1’2 and to inhibit proteoglycan synthesis. 3,4 IL-1 is
known to be an inducer of other cytokines such as
IL-65 and the colony stimulating factors (CSFs), and
induces adhesion molecules on endothelial cells
and chemotactic cytokines such as IL-8. IL-1 can
augment the immune response,9,1 contribute to the
formation of granulation tissue11’12 and play a role in
nonspecific immunity. 13 All these events are part of
the inflammatory process.
IL-1 has been shown to produce inflammation and
cartilage proteoglycan loss when injected
intraarticularly in the rabbit, 14-16 mouse17 and rat.8
Moreover, IL-1 has been shown to have direct in-
volvement in a murine19 and in a rat model2 of
arthritis. Previously, it has been shown that systemic
administration of IL-1 can lead to decreased
locomotor activity in the rat, measured as rearing
activity and movement from one quadrant of the
cage to another. 21 The possibility was considered that
a local arthritis might also affect locomotor activity.
However, preliminary studies of activity in locomotor
cages showed only minor effects of arthritis on
movement, perhaps because of the limited range of
movement possible in a 30 x 45 cm cage. A running
wheel offered the possibility of extended running
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activity that could be modified by arthritis. However,
the normal untrained rat shows highly variable run-
ning. In contrast, a hamster without training will
travel many kilometres a night on a wheel or disk
22
and therefore seemed a better species in which to
explore the effects of arthritis on mobility. Thus, the
consequences of an arthritis induced by local
intraarticular administration of IL-1 on mobility of the
hamster were studied.
Methods
Animal care and housing: Female Golden Syrian
hamsters (Mesocricetus auratus) strain
LAK.LVG(SYR) were purchased from Charles River
Laboratories (Kingston, NY) at 100-110g weight.
They were maintained on a 10/14 light cycle with
food and water ad libitum and were acclimatized to
our facility for at least a week in standard housing
before studies were initiated. Hamsters were placed
into cages with 33cm diameter wheels (Nalge,
Rochester, NY) at least 3 days prior to manipulation.
Intraarticular injections: For intraarticular injection,
hamsters were anaesthetized with sodium
pentobarbital (80-100 mg/kg i.p.) generally 1-2 h
before the dark cycle. The treatment groups were
given identical intraarticular injections of 20 lttl IL-10t
or IL-l]3, prepared and characterized as described
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previously,23,24 or phosphate buffered saline (PBS)
vehicle delivered with a 30-gauge needle into both
knees or no injection. The hamsters were weighed,
and returned to their cages. Wheel revolutions were
continuously recorded. On the day of termination of
the experiment, the animals were again anaesthe-
tized, and the left knee was taken for histological
analysis.
Data collection: Wheels were fitted with magnet reed
switches. A 386/25 MHz computer was interfaced
with a 24-channel I/O board to collect real-time data.
Wheel turns were recorded automatically in 1 min
bins and cumulative wheel turns per day recorded.
The wheel turns per day for each animal were re-
corded for 3 to 5 days prior to intraarticular injection
and were averaged to determine a normal daily
distance (NDD) for each animal. Fractional daily
distance for all other days was calculated by dividing
the hamster’s distance on that day by the prior NDD.
Generally, daily data are presented as the average of
the fractional distance of all hamsters in the experi-
mental group _+ S.D. For data in which the movement
characteristics for individual animals were examined
in detail, wheel revolutions were collected in 6 min
(0.1 h) intervals. This facilitated analysis on a PC by
reducing the analysis of data to 240 points per day.
Histology: The hind limbs of control and IL-1 treated
animals were removed and fixed overnight in 10%
neutral buffered formalin (4C). Following fixation,
the knees were decalcified for 72 h in a 1:1 mixture
of 8N formic acid and 1 N sodium formate
(Kristensen’s solution). The knees were then rinsed
for 24 h with cold tap water, and routinely processed
and embedded in paraplast plus. Great care was used
in the mounting of the tissues to ensure that section-
ing would begin perpendicular to the medial side of
the knee. Sections 3 btm thick were cut from the
medial to lateral side of the medial condyle. The
sections were numbered and approximately matched
sections from all animals were routinely stained with
safranin O and fast green and examined using a light
microscope.
Results
Normal runningpattern: The hamsters, when placed
into a cage with a running wheel, quickly adapted to
a consistent running pattern. They generally explore
the cage, shortly discovering the wheel. Most are
soon carrying out tentative exploration of the wheel
motion, and within an hour, most are running as
adeptly as seasoned runners. Almost independently
of the time of day when they are placed in the cage,
they will run greater than 90% of what will become
their standard running distance that first night. Ex-
cept for the exploratory behaviour of the first day,
the daily running distance of the normal hamster
appears largely constant from day to day over a
10-12 day experimental period, and occurs exclu-
sively during the dark portion of the light cycle.
Intraarticular IL-I: As an initial test to determine
whether IL-1 induced inflammation would affect
running, we chose to examine an amount of IL-10t
(40 ng) that was four times the amount used to give
inflammation, inhibition of proteoglycan synthesis
and, after three injections, frank proteoglycan loss in
the mouse. 17 The amount reflected a compromise
between the differences in dose scaling based on
surface area (3 x) and body weight (5 x) of a 125 g
hamster and a 25 g mouse. 25 Results of a typical
experiment are shown in Fig. 1. The normal nightly
distance was determined using the 5 days of running
prior to the IL-1 injection. After intraarticular IL-1
injection, there is approximately a 40% decrease from
the normal daily running distance compared with
saline injected controls.
The hamsters were allowed to run for a second
night after the primary IL-1 treatment. Running dis-
tance was essentially normal. A second injection of
IL-1 was then given. As shown in Fig. 1, a much more
dramatic inhibition of running was observed after the
second exposure to IL-1. In this experiment a mean
decrease of 84% from the NDD was found. Surpris-
ingly, even with this much more pronounced sup-
pression of running on night 2, when left to run
again on the following night, they ran essentially
normal distances.
To examine the relationship between tissue in-
flammation, cartilage proteoglycan loss, and restora-
tion of mobility, histological sections were taken of
the IL-l-injected, the PBS injected, and the control
animals after the animals had completed their second
night’s run, approximately 40 h following their sec-
ond intraarticular IL-1 injection.
Histological sections from the PBS injected con-
trois were free from all signs of inflammation. The
10 11
IL-1 IL-1
FIG. 1. The effect of intraarticular IL-1 on normal nightly distance. Hamsters
(n= 12) were allowed to run for 5 nights and a normal nightly distance
calculated (NDD 9.3 + 0.3 km). Six hamsters were injected with 40 ng IL-
lx and six were injected with saline. The NDD was recorded for the next
2 nights. The hamsters were again injected with 40 ng of IL-1 or saline and
allowed to run for another 2 nights.
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soft tissue was free of leukocyte influx (Fig. 2A) and
the cartilage proteoglycan staining was normal (Fig.
3A). Sections from the IL-1 treated animals showed
clear and unmistakable inflammation of the sur-
rounding soft tissue. There was a heavy leukocyte
infiltration into both the deep and superficial soft
tissue (Fig. 2B). There was an extensive loss of
proteoglycan from the non-calcified layer of the
cartilage as demonstrated by loss of safranin O stain-
ing, particularly in the pericellular regions which
show the most intense staining (Fig. 3B). The
synovial fluid continued to show evidence of a mild
cellular infiltration and residual fibrin deposits. No
comparable changes were observed in either the
saline injected or control, non-injected hamsters.
Dose response: The effect of the amount of IL-1 on
normal daily distance was examined. IL-I was given
intraarticularly in amounts of 10, 20 and 40 ng. Good
inhibition of running by IL-1 was observed at all
three doses with a dose responsiveness inhibition of
nightly distance (Fig. 4). The ED50 is estimated to be
about 10 ng/joint. As was observed in the previous
experiments, the inhibition of running was much
more extensive after the second IL-1 injection when
compared with the first injection of IL-1.
Effect ofIL-l vs. IL-I: Experiments were carried
out to determine whether there was a detectable
difference in activity between IL-10t and IL-I, and
whether there was any evidence of a synergistic
interaction between the two forms of IL-1. In previ-
ous experiments, 20 ng of IL-1 intraarticularly gave
an intermediate response and therefore, that dose
was chosen to be tested. One group received 20 ng
of IL-I, a second group received 20 ng IL-I, a third
FIG. 2. Histology of the joint capsule 40 h after the second intraarticular injection saline (a), or 40 ng of IL-I (b). The tissue sections were stained
with safranin O and counterstained with fast green. In Fig. a, the typical appearance of a non-inflamed knee can be seen. There were few cells in
the soft connective tissue surrounding the joint (c) and there was no hypertrophy of the synovial lining cells (arrows). In contrast, the effects of the
IL-la injections were clearly visible (Fig. b). There was a perceptible increase in the thickness and cellular content of the soft connective tissue
surrounding the joint. In addition, hypertrophy of the synovial lining cells (arrows) was readily apparent. (Magnification 40 x).
FIG. 3. Histology of the articular cartilage 40 h after the second intraarticular injection of saline (a), or of 40 ng of IL-I (b). The saline injections did
not result in any loss of proteoglycan from the articular surface of the femoral condyle (arrowheads) nor as any cell or proteinaceous material present
in the synovial space, (s). In the IL-le injected knees, the cartilage proteoglycan was depleted down to the tidemark (arrowheads) and there was
an influx of cells and fluid into the joint spaces, (s). (Magnification 100 x).
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FIG. 4. Dose responsive inhibition of normal nightly distance after
intraarticular injection of IL-lo. Hamsters were allowed to run for 3 nights
and a normal nightly distance of 9.3 km/night was found. On the fourth day
they were injected with IL-lcz, and allowed to run for the following 2 nights.
A second intraarticular injection of IL-1 was given and that night’s distance
recorded. The mean fractional distance for each group of six hamsters is
plotted as a function of the intraarticular IL-l(z.
group received 10 ng IL-Iz and 10 ng of IL-113, and
a control group received only PBS. The results are
given in Fig. 5. No difference was observed between
the response to IL-10t and IL-113, nor was there any
evidence of either synergism or antagonism of one
form of IL-1 for the other.
Effect of intraperitoneal administration of IL-lo: It
has been shown previously that IL-1 given intraperi-
toneally can inhibit mobility.
21 Therefore the possibil-
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FIG. 5. Comparison of the effects of IL-lo and IL-11 on mobility inhibition
in the hamster. Four groups of six hamsters were allowed to run for 4 nights
and a normal nightly distance calculated for each hamster. The fractional
nightly distance is shown for each group of hamsters for the night prior to
the first IL-1 injection (night 1), for the night following the first IL-1 injection
(night 0) and for the night following the second intraarticular injection (night
2). Four groups of six hamsters were examined. From left to right, the
groups are 20 pl PBS, 20 ng IL-l(z, 20 ng IL-11, and 10 ng IL-lo plus 10 ng
IL-11.
ity was considered that the effect of intraarticularly
administered IL-1 is either purely local, that is, caused
by local changes at the site of injection, or might be
caused by IL-I{z or secondary mediators suffusing
from the joint to cause a central inhibition of mobil-
ity. The effects of an 80 ng dose of IL-10t adminis-
tered intraperitoneally (comparable with the highest
intraarticular IL-lz dose) were compared with the
effects of a l btg dose of IL-10t administered
intraperitoneally, a dose that had previously been
found necessary to inhibit mobility in the rat. The
results (Fig. 6) demonstrate that no inhibition of
mobility was observed after intraperitoneal adminis-
tration of the 80 ng dose. However, a modest, but
significant, inhibition of mobility was observed when
1 l.tg of IL-10t was administered intraperitoneally.
Discussion
Modelling changes that take place in mobility
during human arthritis by studying the effects of
arthritis in animals has not previously been done.
Such studies in animals have advantages. Arthritis
can be induced acutely and thus changes in mobility
parameters can be referred directly back to previ-
ously normal values. The effects of different types of
arthritis can be explored, and changes in mobility can
be related to biochemical, histological and pain
parameters studied during the experiment. As an
initial test of this hypothesis, intraarticular IL-1 was
used as an arthritogen principally because it causes
a mild and reversible arthritis’6 and it was speculated
that its effects would be primarily local under these
circumstances. Thus, some of these conclusions
may not be applicable to chronic arthritis where an
overlay of systemic disease may change mobility in
a fundamental way. Recognizing these qualifica-
tions, we still felt that simplicity dictated examination
of the consequences of an acute local inflammation
on mobility.
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FIG. 6. Comparison of 80 ng IL-lo and g IL-lcz given intraperitoneally.
Groups of six hamsters were allowed to run for 3 nights, and a normal
nightly distance computed for each hamster. On day 3, IL-lo was admin-
istered intraperitoneally and the nightly distance determined.
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It was verified that intraarticular IL-1 induced joint
inflammation in the hamster. Histologically, as ex-
pected from observations in other species, cell infil-
tration, soft tissue swelling, and proteoglycan loss
were observed. The inflammation after a second
IL-1 injection was greater than that after the first
injection. A single intraarticular saline injection did
not prime the joint to a greater response to a subse-
quent IL-1 injection (data not shown). It is suspected
that the enhanced effect of the second IL-1 injection
is due to its adminisration into an already inflamed
joint. It has previously been shown that intraarticular
IL-1 leads to potentiation of the smoldering arthritis
induced with streptococcal cell wall peptidoglycan
inducing development of much more extensive
pannus, soft tissue swelling and cartilage destruc-
tion. ’7 Thus, it appears that application of IL-1 to a site
already infiltrated by inflammatory cells finds the
tissue in a position to respond more readily to IL-1.
The second intraarticular injection of IL-1 into a site
is also characterized by a greater suppression of daily
running distance than the first injection.
When the amount of IL-1 required to obtain an
effect on mobility was measured, it was found that
a good dose response was obtained in the range of
10-40 ng of IL-1 per joint. This is consistent with the
amount of IL-1 which causes histopathological
changes and cartilage depletion in mice. 17 Although
this amount is well above the levels of IL-1 that can
be measured in biological fluids, the rapid distribu-
tion and elimination in rodents of murine IL-I and
28 and human IL-I
29’3 means that much larger
amounts will be required by bolus injection to match
that generated by continuous local production.
Moreover, as described above, it is likely that the
amount of IL-1 required to amplify an existing inflam-
matory lesion is much less than the amount of IL-1
required to elicit a full blown inflammation de
nouveau. Thus, although it is considered that the
amount of IL-1 utilized in these experiments is super-
physiological, the changes produced probably reflect
those seen following endogenous production.
IL-lot and IL-I[ have both been shown to bind
equally to the IL-I type receptor whereas the type
II receptor has been characterized by a preferential
binding of IL-I.
31 The comparable effectiveness of
IL-lot and IL-I[ in inhibition of mobility implies they
are acting at the type receptor. It has been shown
previously by antibody blocking experiments that
both IL-lo: and IL-I are involved in inflammation
and inhibition of proteoglycan synthesis during
arthritis. 19 However, Perretti et al.2 have reported
that peritoneal leukocyte infiltration is predomi-
nantly IL-I[ dependent, and for effects more distal
from the site of inflammation, i.e. weight loss and
fever,4 a selective IL-I dependency has been found.
The possibility that inhibition of mobility could be
attributed to systemic rather than local effects was
investigated. It has been found previously that con-
tinuous administration of IL-I intraperitoneally in
rats leads to inhibition of mobility without local joint
pathology.
21 Thus we wondered if the amount of
IL-1 given intraarticularly was sufficient to cause
systemic inhibition of mobility. A dose of 1 btg of
IL-I injected intraperitoneally inhibited mobility
with an effect that was comparable with 20 ng/joint
intraarticularly (40 ng total). Sadaro and Dunn35 using
direct intracerebroventricular injection of 77ng
murine IL-I{x into mice failed to observe a change in
locomotor activity. However, they did observe a
reduction in exploratory behaviour to novel stimuli.
Dunn et al.6 reported a decrease in exploratory
behaviour at 10 ng i.p. in the rat, but no change in
locomotor activity. Thus there is greater inhibition of
mobility when IL-1 is given locally rather than sys-
temically.
The nature of the joint inflammation may also
affect the outcome of the mobility studies. By using
IL-1, a mild inflammatory stimulus was chosen that
leads to soft tissue swelling and proteoglycan loss.
The articular cartilage is not innervated and it would
not be expected to contribute to the loss of mobility.
The synovium is, by contrast, known to be inner-
vated and pressure sensitive efferents could transmit
a signal suppressing mobility. Surprisingly, in spite
of continuing inflammation and soft tissue swelling
of the synovium, no impairment of mobility was
found the second night after either the first or the
second IL-1 injection. This may mean that IL-1 itself,
or secondary mediators such as prostaglandins, di-
rectly sensitize pain receptors and thus there is im-
pairment of mobility only while the mediators are
present. Alternatively, the initial soft tissue swelling
may lead to pain, but stress relaxation of the tissue
occurs with time (i.e. accommodation of the tissue to
distension), and, with stress relaxation, the
hyperalgesic response may be lost in tle absence of
continuing additional inflammatory pressure. Finally,
it is also possible that there has been direct evolu-
tionary pressure toward preserving mobility.
Hukkanen et al. and Mapp et al. have demonstrated
the loss of sensory nerve fibres in inflamed synovium
in adjuvant arthritic rats: and human rheumatoid
arthritic patients,8 respectively. Mobility compro-
mised by joint inflammation would limit foraging and
thus have a negative impact on survival and repro-
duction. Thus, the rapid restoration of mobility to
normal in the presence of continuing inflammation
of the joints may be an evolutionary outcome.
References
1. Dingle JT, Saklatvala J, Hembry RM, Tyler JA, Fell HB, Jubb R. A cartilage catabolic
factor. BiochemJ 1979; 154: 177-180.
2. Saklatvala JL, Pilsworth LMC, Sarsfield SJ, Gavrilovic J, Heath JK. Pig catabolin is
form of interleukin-1. BiochemJ 1984; 224: 461-466.
3. Tyler JE. Chondrocyte-mediated depletion of articular cartilage proteoglycans in
vitro. BiochemJ 1985; 225: 493-507.
Mediators of Inflammation. Vol 3. 1994 203I. G. Otterness, M. L. Bliven and A. J. Milici
4. den Berg WB, de Loo FAJ, Zwarts WA, Otterness IG. Effects of murine
recombinant interleukin intact homologous articular cartilage: quantitative
and autoradiographic study. Ann Rheum Dis 1988; 4"/: 855-863.
5. McIntosh JDM, Mule JJ, Nordan RP, Rudikoff S, Lotze MT, Rosenberg SA. In vivo
induction of IL-6 by administration of exogenous cytokines and detection of de
levels of IL-6 in tumor-bearing mice. Jlmmunol 1989; 143: 162-167.
6. Fibbe WE, Van Damme, AJB, Voogt PJ, Duinkerken N, Kluck PMC, Falkenburg JHF.
Interleukin-1 (22-K factor) induces release of granulocyte-macrophage colony-
stimulating activity from human mononuclear phagocytes. Blood 1986; 68:
1316-1321.
7. Pohlman TH, Stanness KA, Beatty PG, Ochs DH, Harlan JM. An endothelial cell
surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, tumor
necrosis factor- increases neutrophil adherence by CDw 18-dependent mecha-
nism. Jlmmuno11986; 13{;: 4548-4553.
8. DeMarco D, Kunkel SL. IL-l-induced gene expression of neutrophil activating
peptide (IL-8) and monocyte chemotatic peptide in human synovial cells. Biochem
Biophys Res Commun 1991; 1"/4: 411-416.
9. Kaye J, Gillis S, Mizel SB, et al. Growth of cloned helper T cell line induced by
monoclonal antibody specific for the antigen receptor: interleukin is required
for the expression of receptors for interleukin-2. JImmuno11984; 133: 1339-1345.
10. Chiplunkar S, Langhorne J, Kaufmann SHE. Stimulation of B cell growth and
differentiation by murine recombinant interleukin-1. J Immunol 1986; 13"/:
3748-3752.
11. Dunn C, Hardee M, Staite ND. Acute and chronic inflammatory responses to local
administration of recombinant IL-I, IL-I, TNF and IFN, in mice. Agents Actions
1989; 2"/: 290-293.
12. Otterness IG, Golden HW, Brissette WH, Seymour PA, Daumy GO. Effects of
continuously administered murine interleukin-la: tolerance development and
granuloma formation. Infect Immun 1989; 5"/: 2742-2750.
13. Havell EA, Moldawer LL, Helfgott D, Kilian PL, Sehgal PB. Type receptor blockade
exacerbates murine listeriosis. Jlmmunol 1992; 145: 1486-1492.
14. Pettipher ER, Higgs GA, Henderson B. Interleukin induces leukocyte infiltration
and cartilage proteoglycan degradation in the synovial joint. Proc NatlAcad Sci USA
1986; 83: 8749-8753.
15. Dingle JT, Page TPD, King B, Bird DR. In vivo studies of articular tissue damage
mediated by catabolin/interleukin 1. Ann Rheum Dis 1987; 4{: 527-533.
16. Feige U, Karbowski A, Rordorf-Adam C, Pataki A. Arthritis induced by continuous
infusion of hr-interleukin-la into the rabbit knee-joint. IntJ Tissue Reac 1990; 11:
225-238.
17. de Loo AAJ, den Berg WB. Effects of murine recombinant interleukin
synovial joints in mice: measurement of patellar cartilage metabolism and joint
inflammation. Ann Rheum Dis 1990; 49: 238-245.
18. Chandraskar S, Harvey AK, Hurbey PS, Bendele AM. Arthritis induced by
interleukin-1 is dependent the site and frequency of intraarticular injection. Clin
Immunollmmunopathol 1990; 55: 382-400.
19. de 1oo FAJ, Arntz OJ, Otterness IG, den Berg WB. Protection against
cartilage proteoglycan synthesis inhibition by antiinterleukin antibodies in experi-
mental arthritis. JRheumatol 1992; 19: 348-356.
20. Schwab JH, Anderle SK, Brown RR, Dalldorf FG, Thompson RC. Pro- and anti-
inflammatory roles of interleukin-1 in of bacterial cell wall-induced
arthritis. Infect Immun 1991; 59: 4436-4442.
21. Otterness IG, Seymour PA, Golden HW, Reynolds JA, Daumy GO. The effects of
continuous administration of murine interleukin-la in the rat. Physiol Behav 1988;
43: 787-804.
22. Borer KT. Characteristics of growth-inducing exercise. Physiol Behav 1980; 24:
713-720.
23. Daumy GO, Merenda JM, McColl AS, et al. Isolation and characterization of
biologically active murine interleukin-l from expression of synthetic gene in
Escherichia coli. Biochem Biophys Acta 1989; 998: 32-42.
24. Daumy GO, Wilder CL, Merenda JM, McColl AS, Geoghegan KF, Otterness IG.
Reduction of biological activity of murine recombinant interleukin-l[ by selective
deamidation at asparagine-149. FEBS Lett 1991; :a"/8: 98-102.
25. Otterness IG, Gans DJ. Nonsteroidal anti-inflammatory drugs: analysis for the
relationship between laboratory animal and clinical doses, including species scal-
ing. J Pharm Sci 1988; "/"/: 790-795.
26. de Loo FAJ, Arntz OJ, den Berg WB, Otterness IG. Proteoglycan loss and
subsequent replenishment in articular cartilage after mild arthritic insult by IL-1
in mice: impaired proteoglycan turnover in the recovery phase. AgentsActions 1994
(in press).
27. Stimpson SA, Dalldorf FG, Otterness IG, Schwab JH. Exacerbation of arthritis by
IL-1 in rat joints previously injured by peptidoglycan-polysaccharide. J Immunol
1988; 14{}: 2964-2469.
28. Banks WA, Ortiz L, Plotkin SR, Kastin AJ. Human interleukin (IL) 10t, murine
IL-10t and murine IL-l[8 transported from blood to brain in the by
shared saturable mechanism. J Pharm Exp Ther 1992; 259: 988-996.
29. Newton RC, Uhl J, Covington M, Black O. The distribution and clearance of
radiolabeled human interleukin-l[ in mice. Lymphokine Res 1988; "/: 207-215.
30. Reimers J, Wogensen LD, Welinder B, et al. The pharmacokinetics, distribution and
degradation of human recombinant IL-1 beta in normal rats. ScandJImmuno11991;
34: 597-610.
31. Chizzonite R, Truitt T, Kilian PL, et al. Two high affinity interleukin receptors
represent separate gene products. Proc Natl Acad Sci USA 1989; 8{: 8029-8033.
32. Peretti M, Solito E, Parente L. Evidence that endogenous interleukin-1 is involved
in leukocyte migration in acute experimental inflammation in rats and mice. Agents
Actions 1992; 35: 70-78.
33. Otterness IG, Bliven JL, Carreras I, Sipe JD. In vivo roles of IL-I and IL-I. Cytokine
1991; 3: 513.
34. Long NC, Otterness IG, Kunkel SL, Vander AJ, Kluger MJ. Roles of interleukin lb
and tumor necrosis factor in lipopolysaccharide fever in rats. AmJPhysio11990; 28:
R724-R728.
35. Sapadaro F, Dunn AJ. Intracerebroventricular administration of interleukin-1 to
mice alters investigation of stimuli in novel environment. Brain Behav Immunol
1990; 4: 308-322.
36. Dunn AJ, Antoon M, Chapman Y. Reduction of exploratory behavior by
intraperitoneal injection of interleukin-1 involves brain corticotropin-releasing
factor. Brain Res Bull 1991; :a{: 539-542.
37. Hukkanen M, Gr6nblad M, Rees R, et al. Regional distribution of mast cells
and peptide containing in normal and adjuvant arthritic rat synovium.
JRheumatol 1991; 18: 177-183.
38. Mapp PI, Kidd BL, Gibson SJ, et al. Substance P-, calcitonin gene-related peptide-
and C-flanking peptide of neuropeptide Y-immunoreactive fibers present in
normal synovium but depleted in patients with rheumatoid arthritis. Neuroscience
1991; 3"/: 143-153.
ACKNOWLEDGEMENT. The authors thank Deborah Scampoli for cutting and preparing
the tissue sections.
Received 26 January 1994;
accepted in revised form 28 February 1994
204 Mediators of Inflammation Vol 3. 1994